Bristol wants Gilead to study drug combo for hepatitis C

Bristol-Myers Squibb CEO Lamberto Andreotti urged Gilead Sciences to conduct a Phase III trial combining Gilead's GS-7977 and -More- …
Read the full story: BIO SmartBrief